RubrYc Therapeutics, Inc. (“RubrYc”) and iBio, Inc. (“iBio”, NYSEA: IBIO) announced today the closing of RubrYc’s Series A2 Preferred Financing, and concomitant License and Collaboration Agreements directed towards the …
RubrYc Therapeutics announces Series A2 Preferred equity financing, collaboration, and RTX-003 license with iBio, Inc.
